Cargando…

Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China

PURPOSE: Non-small-cell lung cancer (NSCLC) is the most diagnosed lung cancer and is associated with poor prognosis. This study aimed to analyze whether fasting blood glucose (FBG) levels could provide prognostic information in Chinese patients with NSCLC, using the Suzhou Lung Cancer Survival study...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jin-Rong, Chen, Guo-Chong, Xu, Jia-Ying, Ling, Chen-Jie, Yu, Na, Yang, Jing, Zeng, Da-Xiong, Gu, Min-Jing, Li, Da-Peng, Zhang, Yu-Song, Qin, Li-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662513/
https://www.ncbi.nlm.nih.gov/pubmed/31413592
http://dx.doi.org/10.2147/OTT.S210103
_version_ 1783439669834285056
author Yang, Jin-Rong
Chen, Guo-Chong
Xu, Jia-Ying
Ling, Chen-Jie
Yu, Na
Yang, Jing
Zeng, Da-Xiong
Gu, Min-Jing
Li, Da-Peng
Zhang, Yu-Song
Qin, Li-Qiang
author_facet Yang, Jin-Rong
Chen, Guo-Chong
Xu, Jia-Ying
Ling, Chen-Jie
Yu, Na
Yang, Jing
Zeng, Da-Xiong
Gu, Min-Jing
Li, Da-Peng
Zhang, Yu-Song
Qin, Li-Qiang
author_sort Yang, Jin-Rong
collection PubMed
description PURPOSE: Non-small-cell lung cancer (NSCLC) is the most diagnosed lung cancer and is associated with poor prognosis. This study aimed to analyze whether fasting blood glucose (FBG) levels could provide prognostic information in Chinese patients with NSCLC, using the Suzhou Lung Cancer Survival study. PATIENTS AND METHODS: A prospective cohort study of adult patients with primary NSCLC was performed. The patients who were hospitalized between January 2016 and April 2018 in two hospitals affiliated with Soochow University were recruited. Patient information, including lifestyle habits and clinical and laboratory data, were collected through face-to-face interviews and evaluation of medical records. Follow-up was initiated from the date of patient enrollment until May 8, 2018 or until patient death. The long-term survival of patients was assessed every 6 months. Patient vital status was confirmed by using hospital records, telephone interview, or local death registration system. Cox proportional hazards regression was used to estimate hazard ratio and 95% confidence interval (CI) for death, with adjustment for cancer stage, medical treatments, smoking, and other potential confounders. RESULTS: A total of 387 patients were included in the analysis, and the numbers (percentages) of patients with stages I, II, III, and IV NSCLC were 53 (13.7%), 41 (10.6%), 64 (16.5%), and 215 (55.6%), respectively. The median duration of follow-up was 19.1 months. Compared with patients in the second tertile of FBG, the HRs for mortality were 2.16 (95% CI: 1.26–3.73) and 1.87 (95% CI: 1.03–3.42) for those in the lowest one and diabetic group, respectively. Subgroup analysis according to various patient characteristics confirmed these associations. CONCLUSION: Diabetes and low FBG could be important predictors of death in patients with NSCLC. Maintaining appropriate blood glucose levels may improve prognosis in patients with NSCLC.
format Online
Article
Text
id pubmed-6662513
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66625132019-08-14 Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China Yang, Jin-Rong Chen, Guo-Chong Xu, Jia-Ying Ling, Chen-Jie Yu, Na Yang, Jing Zeng, Da-Xiong Gu, Min-Jing Li, Da-Peng Zhang, Yu-Song Qin, Li-Qiang Onco Targets Ther Original Research PURPOSE: Non-small-cell lung cancer (NSCLC) is the most diagnosed lung cancer and is associated with poor prognosis. This study aimed to analyze whether fasting blood glucose (FBG) levels could provide prognostic information in Chinese patients with NSCLC, using the Suzhou Lung Cancer Survival study. PATIENTS AND METHODS: A prospective cohort study of adult patients with primary NSCLC was performed. The patients who were hospitalized between January 2016 and April 2018 in two hospitals affiliated with Soochow University were recruited. Patient information, including lifestyle habits and clinical and laboratory data, were collected through face-to-face interviews and evaluation of medical records. Follow-up was initiated from the date of patient enrollment until May 8, 2018 or until patient death. The long-term survival of patients was assessed every 6 months. Patient vital status was confirmed by using hospital records, telephone interview, or local death registration system. Cox proportional hazards regression was used to estimate hazard ratio and 95% confidence interval (CI) for death, with adjustment for cancer stage, medical treatments, smoking, and other potential confounders. RESULTS: A total of 387 patients were included in the analysis, and the numbers (percentages) of patients with stages I, II, III, and IV NSCLC were 53 (13.7%), 41 (10.6%), 64 (16.5%), and 215 (55.6%), respectively. The median duration of follow-up was 19.1 months. Compared with patients in the second tertile of FBG, the HRs for mortality were 2.16 (95% CI: 1.26–3.73) and 1.87 (95% CI: 1.03–3.42) for those in the lowest one and diabetic group, respectively. Subgroup analysis according to various patient characteristics confirmed these associations. CONCLUSION: Diabetes and low FBG could be important predictors of death in patients with NSCLC. Maintaining appropriate blood glucose levels may improve prognosis in patients with NSCLC. Dove 2019-07-23 /pmc/articles/PMC6662513/ /pubmed/31413592 http://dx.doi.org/10.2147/OTT.S210103 Text en © 2019 Yang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Jin-Rong
Chen, Guo-Chong
Xu, Jia-Ying
Ling, Chen-Jie
Yu, Na
Yang, Jing
Zeng, Da-Xiong
Gu, Min-Jing
Li, Da-Peng
Zhang, Yu-Song
Qin, Li-Qiang
Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China
title Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China
title_full Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China
title_fullStr Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China
title_full_unstemmed Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China
title_short Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China
title_sort fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662513/
https://www.ncbi.nlm.nih.gov/pubmed/31413592
http://dx.doi.org/10.2147/OTT.S210103
work_keys_str_mv AT yangjinrong fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT chenguochong fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT xujiaying fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT lingchenjie fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT yuna fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT yangjing fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT zengdaxiong fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT guminjing fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT lidapeng fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT zhangyusong fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina
AT qinliqiang fastingbloodglucoselevelsandprognosisinpatientswithnonsmallcelllungcanceraprospectivecohortstudyinchina